Clinical Trial Update: Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial update for a personalized KXV01 TCR Lentinvivo Injection intended to treat advanced solid tumors; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• KXV01 TCR Lentinvivo Injection

Snippet

Sponsor: The First Hospital of Jilin University | Conditions: Advanced Solid Tumors | Phase 1 | Status: NOT_YET_RECRUITING